Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma

被引：29

作者：

Chen, Robert ^{[1
]}

Palmer, Joycelynne M. ^{[2
]}

Popplewell, Leslie ^{[1
]}

Shen, Jessica ^{[2
]}

Smith, Eileen ^{[1
]}

Delioukina, Maria ^{[1
]}

Kogut, Neil ^{[3
]}

Rosenthal, Joseph ^{[4
]}

Forman, Stephen ^{[1
]}

Nademanee, Auayporn ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol Hematopoiet Cell Transplantat, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Div Biostat, Duarte, CA 91010 USA

[3] City Hope Kaiser Permanente, Los Angeles, CA USA

[4] City Hope Natl Med Ctr, Dept Pediat Hematopoiet Cell Transplantat, Duarte, CA 91010 USA

来源：

ANNALS OF HEMATOLOGY | 2011年 / 90卷 / 07期

关键词：

Allogeneic transplant; Reduced intensity; Hodgkin lymphoma; Relapsed; HL; BONE-MARROW TRANSPLANT; SALVAGE THERAPY; PHASE-II; DISEASE; TRIAL; REGIMEN; CHEMOTHERAPY; GEMCITABINE; EXPERIENCE; HYBRID;

D O I：

10.1007/s00277-010-1146-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hodgkin lymphoma (HL) can be aggressive and intractable in some cases. Patients who relapse after autologous HCT (auto-HCT) have limited treatment options. City of Hope reports our experience in the use of reduced intensity allogeneic hematopoietic cell transplantation (allo-HCT) in 24 heavily pretreated patients with relapsed HL, between January 2003 and December 2008. The median number of prior therapies was 5; 20/24 patients had prior auto-HCT. The conditioning regimen for all patients was fludarabine and melphalan. With a median follow-up for living patients of 39.0 months, at 2 years the overall survival (OS) was 60% (95% CI 42, 72) and the progression-free survival was 27% (95% CI 22, 32). Non-relapse mortality was 13.1% (95% CI 5.1, 31.4) at 2 years. The incidence of grade II-IV aGVHD was 45.8% and 8.3% for grade III-IV. Allo-HCT in heavily pretreated relapsed Hodgkin lymphoma is feasible, tolerable, and can induce durable clinical remissions.

引用

页码：803 / 808

页数：6

共 50 条

[1] Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma
Robert Chen
Joycelynne M. Palmer
Leslie Popplewell
Jessica Shen
Eileen Smith
Maria Delioukina
Neil Kogut
Joseph Rosenthal
Stephen Forman
Auayporn Nademanee
[J]. Annals of Hematology, 2011, 90 : 803 - 808
[2] Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma.
Chen, Robert
Palmer, Joycelynne
Popplewell, Leslie
Shen, Jessica
Smith, Eileen
Delioukina, Maria
Kogut, Neil
Rosenthal, Joseph
Forman, Stephen J.
Nademanee, Auayporn P.
[J]. BLOOD, 2009, 114 (22) : 489 - 490
[3] Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
Devetten, Marcel P.
Hari, Parameswaran N.
Carreras, Jeanette
Logan, Brent R.
van Besien, Koen
Bredeson, Christopher N.
Freytes, Cesar O.
Gale, Robert Peter
Gibson, John
Giralt, Sergio A.
Goldstein, Steven C.
Gupta, Vikas
Marks, David I.
Maziorz, Richard T.
Vase, Julie M.
Lazarus, Hillard M.
Anderlini, Paolo
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (01) : 109 - 117
[4] Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
Chen, Robert
Palmer, Joycelynne M.
Thomas, Sandra H.
Tsai, Ni-Chun
Farol, Len
Nademanee, Auayporn
Forman, Stephen J.
Gopal, Ajay K.
[J]. BLOOD, 2012, 119 (26) : 6379 - 6381
[5] Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma
Paillard, C.
Salmon, A.
Curtillet, C.
David, A.
Halle, P.
Cachin, F.
Bordigoni, P.
Michel, G.
Rousseau, R.
Dore, E.
Isfan, F.
Merlin, E.
Rochette, E.
Demeocq, F.
Kanold, J.
[J]. PEDIATRIC TRANSPLANTATION, 2010, 14 (01) : 109 - 114
[6] ALLOGENEIC STEM CELL TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING REGIMEN IN PATIENTS WITH RELAPSED HODGKIN'S LYMPHOMA
Marta Rivas, M.
Berro, M.
Virginia Prates, M.
Yantorno, S.
Milone, J.
Lisa Basquiera, A.
Adriana, B.
Jose Garcia, J.
Remaggi, G.
Martinez Rolon, J.
Burgos, R.
Foncuberta, C.
Feldman, L.
Jaimovich, G.
Real, J.
Milovic, V.
Arberbide, J.
Makiya, M.
Dibar, E.
Kusminsky, G.
[J]. BONE MARROW TRANSPLANTATION, 2014, 49 : S172 - S173
[7] Allogeneic Stem Cell Transplantation With Reduced Intensity Conditioning Regimen In Patients With Relapsed Hodgkin's Lymphoma
Rivas, Maria Marta
Berro, Mariano
Yantorno, Sebastian
Prates, Maria Virginia
Milone, Jorge H.
Basquiera, Ana Lisa
Berreta, Adriana
Garcia, Juan
Remaggi, Guillermina
Rolon, Juliana Martinez
Arbelbide, Jorge
Makiya, Monica
Dibar, Eduardo
Requejo, Alejandro
Feldman, Leonardo Julio, Sr.
Milovic, Vera
Foncuberta, Maria Cecilia
Burgos, Ruben
Kusminsky, Gustavo Daniel
[J]. BLOOD, 2013, 122 (21)
[8] Donor lymphocyte infusion is an effective therapy for relapsed Hodgkin lymphoma after reduced-intensity allogeneic hematopoietic stem cell transplantation
Oba, Utako
Koga, Yuhki
Suminoe, Aiko
Hara, Toshiro
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 100 (05) : 511 - 513
[9] Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma
Chen, Robert W.
Forman, Stephen J.
Palmer, Joycelynne
Tsai, Ni-Chun
Popplewell, Leslie
Delioukina, Maria L.
Alejandra, Torres
Pulone, Bernadette
Smith, Eileen P.
Nademanee, Auayporn P.
Karanes, Chatchada
O'Donnell, Paul
Maloney, David G.
Farol, Len
Tsai, Schickwann
Grove, Laurie E.
Gopal, Ajay K.
[J]. BLOOD, 2011, 118 (21) : 304 - 305
[10] Donor lymphocyte infusion is an effective therapy for relapsed Hodgkin lymphoma after reduced-intensity allogeneic hematopoietic stem cell transplantation
Utako oba
Yuhki Koga
Aiko Suminoe
Toshiro Hara
[J]. International Journal of Hematology, 2014, 100 : 511 - 513

← 1 2 3 4 5 →